Back to contents
«Messenger of Anesthesiology and Resuscitation» Vol 14, №6, 2017,

DOI : 10.21292/2078-5658-2017-14-6-6-20

Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy

YU. S. POLUSHIN 1 , D. V. SOKOLOV 1 , D. YU. BELOUSOV 2 , А. E. CHEBERDА 2

  • 1 Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
  • 2 Center of Pharmacoeconomics Research, Moscow, Russia

Lately, in Russia, the number of patients with severe stage of acute renal failure requiring renal replacement therapy is increasing. Intermittent hemodialysis is the most common type of this therapy, however, the continuous methods of renal replacement therapy also started to be more often used in clinical practice despite of their high basic cost. The subject of this study is to investigate of pharmaco-economic results reflecting direct medical and indirect non-medical costs when using these technologies versus the maximum effective use of funds while treating patients with severe renal dysfunctions.
Objective: to perform comparative clinical and economic analysis of intermittent and continuous renal replacement therapy in the intensive care wards of medical units in Russia.
Methods. The study was conducted in compliance with acting Standards on Clinical Economic Studies used in Russian Federation. The study methods included evaluation of existing randomized clinical studies and trials which included data from network meta-analyses and systematic reviews of the investigated technologies. The direct medical and indirect non-medical costs were calculated and analyzed in respect of cost-effectiveness and costs-utility and budget impact analyses, utility, expressed in the number of saved quality-adjusted life years.
Result: Simulation and comparative healtheconomic analysis of intermittent (IRRT) and continuous (CRRT) renal replacement therapy showed that the use continuous (CRRT) renal replacement therapy resulted in reduction of direct medical and indirect non-medical costs even within the first year. By the end of the third year savings can achieve 341,129.5 RUR per patient, and of this amount, savings in direct medical costs show 279,646.3 RUR and savings of indirect non-medical costs show 61,483.1 RUR. Budget impact analysis identified that using continuous renal replacement therapy (CRRT) allowed to save more than 230 million RUR for the whole country during 3 years per 1,740 patients with acute renal failure.
Conclusion: Despite its high initial costs, the use of CRRT results in the reduction of costs and maximum efficient use of funds, and thus CRRT can be recommended for wider use in the Russian practice.

Key Words: cute renal failure, chronic renal disease, pharmaco-economics, cost-effectiveness, replacement renal therapy, intermittent renal therapy, continuous replacement renal therapy

References

  • 1.Аbdrashitova G.T., Yagudina R.I., Serpik V.G. Pharmaco-economic analysis of medical care for patients with chronic renal disease in need of renal replacement therapy through peritoneal dialysis and hemodialysis in the Russian health system. Farmakoekonomika: Teoriya i Praktika, 2015, vol. 3, no. 3, pp. 103-110. (In Russ.)
  • 2.Andrusev A.M. Peritoneal dialysis and hemodialysis in the patients with terminal stage of chronic renal failure. Comparative efficiency analysis and choice of the method (lecture). Аlmanakh Klin. Meditsiny, 2009, no. 20, pp. 36-45. (In Russ.)
  • 3.Belousov Yu.B., Belousov D.Yu. Osnovy farmakoekonomicheskikh issledovaniy. Uch. posobie. [Basics of pharmaco-economic studies. Handbook]. Moscow, 2000, Natsionalny Fond Sodeystviya Nauchnym I Klinicheskim Issledovaniyam Pri RGMU Publ.
  • 4.Bikbov B.T., Tomilina N.А. On the issue of epidemiology of chronic renal failure in the Russian Federation: analysis of data of the register on replacement renal therapy of the Russian Dialysis Society for 2008-2012. Nefrologiya i Dializ, 2014, vol. 16, no. 4, pp. 453-464. (In Russ.)
  • 5.Bunova S.S., Bilevich O.А., Mikhaylova L.V., Chernyavskaya E.L., Yur N.D. Acute renal failure: causes, outcomes, methods of replacement renal therapy. ONV, 2012, no. 2, (114). (In Russ.)
  • 6.Mukhin N.А., Tareeva I.E. Diagnostika i lechenie bolezney pochek. [Diagnostics and treatment of renal disorders]. Moscow, Meditsina Publ., 1985,
  • 7.Nefrologiya: Rukovodstvo dlya vrachey. [Nephrology. Doctors' guidelines]. I.E. Tareeva, Eds. Moscow, Meditsina Publ., 2000.
  • 8.Standard on Clinical and Economic Studies. General Provisions. Edict no. 163 by the RF Ministry of Health as of 27.05.2002, with OST 91500.14.0001-2002. (In Russ.)
  • 9.Letter no. 11-9/10/2-7938 by the Russian Ministry of Health and Federal Fund of Mandatory Medical Insurance no. 8089/21-i as of December 24, 2015 On Guidelines on the Ways of Medical Care Reimbursement by of Mandatory Medical Insurance Funds. Health care Ministry and Federal Fund for CHI Directive 11-9/10/2- 7938 / 8089/21-i (As of 24.12.2015). (In Russ.)
  • 10.Edict no. 1403 as of 19.12.2016 by the RF Government on the Program of State Guarantees for Free Medical Care Provision for 2017 and Planning for 2018 and 2019. (In Russ.)
  • 11.Price List of the Clinics of Nephrology, Internal and Occupational Diseases named after E.M. Tareev (Epub. in Russ.) URL: http://sechenovclinic.ru/hospitals/detail.php?id=631 (In Russ.)
  • 12.Edict no. 288 by RF Ministry of Health and Social Development as of April 20, 2007 On the Approval of the Standard Medical Care for Stable Angina Patients. (In Russ.)
  • 13.Edict no.1387n by the RF Ministry of Health as of December 24, 2012 On the Approval of the Standard Medical Emergency Care for Those Suffering from Acute Coronary Syndrome without ST-Segment Elevation. (In Russ.)
  • 14.Edict no. 1024n by RF Ministry of Health and Social Development as of December 17, 2015 On the Classification and Criteria Used for Medical Social Appraisal of Citizens by Federal State Organisations Performing Medical and Social Appraisal (with amendments and additions). (In Russ.)
  • 15.Edict no. 659 as of October 19, 2007 On the Approval of the Standard Medical Care for Those Suffering from Streptococcus Septicemia, Other Septicemia and Candidous Septicemia (When Providing Special Care). (In Russ.)
  • 16.Edict no. 1268n as of December 20, 2012 On the Approval of the Standard Specialized Medical Care for Those Suffering from Chronic Renal Disease, Stage 5, Pre-Dialysis Period When Admitted to Hospital to Prepare for Replacement Renal Therapy. (In Russ.)
  • 17.Ryabov S.I., Moysyuk Ya.G. et al. Nephrologiya. [Nephrology]. Vol. 2. Pochechnaya nedostatochnost. Rukovodstvo dlya vrachey. [Renal Failure. Doctors' Guidelines]. SpetsLit. Publ., 2013,
  • 18.Sigitova O.N., Nadeeva R.А., Zakirova V.А., Аrkhipov E.V., Scherbakova А.G. Analysis of chronic renal failure incidence in Tatarstan Republic. Kazansky Med. J., 2008, no. 4. (In Russ.)
  • 19.Tarifnoe soglashenie v sisteme obyazatelnogo meditsinskogo strakhovaniya Belgorodskoy oblasti ot 18 yanvarya 2017 g. [Tariff agreement of mandatory medical insurance in Belgorod Region as of January 18, 2017]. Available at: URL:http://www.belfoms.ru/gts.ht.
  • 20.Federal Law no. 415 FZ as of December 19, 2016 (Revision as of July 01, 2017) On the Federal Budgen for 2017 and planned period of 2018 and 2019. (In Russ.)
  • 21.Federal State Statistics Service, data for 2016. (Epub.) URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/accounts/# (Accessed 02.06.2017). (In Russ.)
  • 22.Federalnaya sluzhba gosudarstvennoy statistiki, dannye za 2016 g. Chislennost i sostav naseleniya v 2016 g. [Federal State Statistics Service, data for 2016. Number and structure of population for 2016]. (Epub.) URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/# (Accessed 11.08.2017).
  • 23.Yagudina R.I., Аbdrashitova G.T., Serpik V.G. Pharmaco-economic analysis of medical care for patients with chronic renal disease in need of renal replacement therapy through peritoneal dialysis and hemodialysis in the Russian health system. Farmakoekonomika: Teoriya i Praktika, 2015, vol. 3, no. 3, pp. 103-110. (In Russ.)
  • 24.Yagudina R.I., Kulikov А.Yu., Krysanov I.S., Litvinenko M.M., Morozov А.L. Specific methods of pharmacoeconomic studies in the health care system of the Russian Federation (review of publication from 1995 to 2007). Farmakoekonomika, 2009, no. 1, pp. 3-6. (In Russ.)
  • 25.Yagudina R.I., Kulikov А.Yu., Metelkin I.А. Methods of cost-effectiveness analysis in pharmacoeconomic research. Farmakoekonomika, Sovremennaya Farmakoekonomika i Farmakoepidemiologiya, 2012, no. 4, pp. 3-8. (In Russ.)
  • 26.Yagudina R.I., Serpik V.G., Аbdrashitova G.T., Kotenko O.N. Economic burden of chronic renal disease in the Russian Federation. Farmakoekonomika: Teoriya i Praktika, 2014, vol. 2, no. 4, pp. 34-39. (In Russ.)
  • 27.Yagudina R.I., Chibilyaev V.А. Use of final and surrogate endpoints in pharmaco-economic studies. Farmakoekonomika, 2010, no. 2, pp. 12-18. (In Russ.)
  • 28.Bagshaw S.M., George C., Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol. Dial. Transplant., 2008, vol. 23, pp. 1569-1574.
  • 29.Bagshaw S.M., Berthiaume L.R., Delaney A. et al. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit. Care Med., 2008, vol. 36, pp. 610-617.
  • 30.Bellomo R., Ronco C., Kellum J.A. et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care, 2004, vol. 8, pp. R204– R212.
  • 31.de Smedt D.M., Elseviers M.M., Lins R.L., Annemans L. Economic evaluation of different treatment modalities in acute kidney injury. Nephrol. Dial. Transplant., 2012, vol. 27, no. 11, pp. 4095-4101.
  • 32.Eloot S., Van Biesen W., Dhondt A., Van de Wynkele H., Glorieux G., Verdonck P., Vanholder R. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int., 2008, vol. 73, pp. 765-770.
  • 33.Ethgen O., Schneider A.G., Bagshaw S.M., Bellomo R., Kellum J.A. Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients. Nephrology Dialysis Transplantation, 2015, vol. 30, no. 1, pp. 54‒61.
  • 34.Farese S., Jakob S.M., Kalicki R., Frey F.J., Uehlinger D.E. Treatment of acute renal failure in the intensive care unit: lower costs by intermittent dialysis than continuous venovenous hemodiafiltration. Artif Organs, 2009, vol. 33, pp. 634-640.
  • 35.Frendshorst W., Finn W., Gottschalk C. Pathogenesis of acute renal failure following renal ischemia in the rat. Circl. Res. 1975, vol. 37, pp. 558‒568.
  • 36.Heung M., Steffick D.E., Zivin K., Gillespie B.W. et al. Acute kidney injury recovery patternand subsequent risk of CKD: An analysis of veterans health administration data. Am. J. Kidney Dis., 2016, vol. 67, pp. 742‒752.
  • 37.Hobson C.E., Yavas S., Segal M.S., Schold J.D., Tribble C.G., Layon A.J. et al. Acute kidney injury is associated with increases long-term mortality after cardiothoracic surgery. Circulation, 2009, vol. 119, pp. 2444–2453. pmid:19398670
  • 38.Hoste E.A., Bagshaw S.M., Bellomo R. et al: Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. 35
  • 39.Hsu R.K., McCulloch C.E., Dudley R.A., Lo L.J., Hsu C.Y. Temporal changes in incidence of dialysis-requiring AKI. J. Am. Soc. Nephrol., 2013, vol. 24, pp. 37-42.
  • 40.Rimes-Stigare C., Frumento P., Bottai M., Martensson J., Martling C.R., Bell M. Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease. Crit. Care, 2015, vol. 19, pp. 383. doi: 10.1186/s13054-015-1101-8.
  • 41.Kellum J.A., Mehta R., Ronco C. Acute dialysis quality initiative (ADQI). Nephrol. Dial. Transplant., 2001, vol. 16. pp. 1555‒1558.
  • 42.Kidney Disease Improving Global Outcomes: KDIGO clinical practice guideline for acute kidney injury. Kidney Int., 2012, vol. 2, pp. 8‒12.
  • 43.Kramer P., Schrader J., Bohnsack W., Grieben G., Grone H.J., Scheler F. Continuous arteriovenous haemofiltration. A new kidney replacement therapy. Proc. Eur. Dial. Transplant., Assoc., 1981, vol. 18, pp. 743-749.
  • 44.Klarenbach S., Manns B., Pannu N. et al. Economic evaluation of continuous real replacement therapy in acute renal failure. Int. J. Tech. Ass. Health Care, 2009, vol. 23, pp. 331-338.
  • 45.Liano F. Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int., 1996, vol. 50, pp. 811-818.
  • 46.Mehta R.L., Kellum J.A., Shan S.V. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care, 2007, vol. 11, pp. 31.
  • 47.Nose Y.Dr., Willem J. Kolff: the godfather of artificial organ technologies. Artif Organs., 2009, vol. 33, pp. 389-402.
  • 48.Schoenfelder T., Chen X., Bleb H.H. Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury. GMS Health Technology Assessment. 2017, 13:Doc01. doi:10.3205/hta000127.
  • 49.Uchino S., Bellomo R., Kellum J.A. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int. J. Artificial Organs, 2007, vol. 30, pp. 281-292.
  • 50.Vanholder R., Sever M.S., Erek E., Lameire N. Rhabdomyolysis. J. Am. Soc. Nephrol., 2000, vol. 11, pp. 1553-1561.
  • 51.Vinsonneau C., Camus C., Combes A., Costa de Beauregard M.A. et al. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet, 2006, vol. 368, pp. 379-385.
  • 52.Waikar S. et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J. Am. Soc. Nephrol., 2006, vol. 17, no. 4, pp. 1143-1150.
  • 53.Wald R., Shariff S.Z., Adhikari N.K. et al. The association between renal replacement therapy modality and long-term outcomes among critically ill adults with acute kidney injury: a retrospective cohort study. Crit. Care Med., 2014, vol. 42, pp. 868-877.
  • 54.Zeng X., McMahon G.M., Brunelli S.M., Bates D.W., Waikar S.S. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin. J. Am. Soc. Nephrol., 2014, vol. 9, pp. 12-20.

For citation: Polushin Yu. S., Sokolov D. V., Belousov D. Yu., Cheberda А. E. Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy «Messenger of Anesthesiology and Resuscitation» 2017; 14(6):6-20. DOI : 10.21292/2078-5658-2017-14-6-6-20


For citation: Polushin Yu. S., Sokolov D. V., Belousov D. Yu., Cheberda А. E. Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy «Messenger of Anesthesiology and Resuscitation» 2017; 14(6):6-20. DOI : 10.21292/2078-5658-2017-14-6-6-20

Для доступа нужна подписка. Войдите в систему для подтверждения ее наличия.